ASH 2023 Lymphoma Recap with Dr. Toby Eyre

In this episode, we review the hottest updates in lymphoma from the American Society of Hematology 2023 meeting with Dr Toby Eyre, a consultant haematologist at the University of Oxford in the UK.
Here are the abstracts that were discussed:
Mantle Cell Lymphoma
1. BOVen trial-A Multicenter Phase 2 Trial of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients with Treatment-Naïve, TP53-Mutant Mantle Cell Lymphoma
ash.confex.com/ash/2023/webpr...
2. SYMPATICO Trial: Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma (Late Breaking Abstract)
ash.confex.com/ash/2023/webpr...
Chronic Lymphocytic Leukemia
1. FLAIR trial: Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease
Link for simultaneous NEJM publication: www.nejm.org/doi/10.1056/NEJM...
2. Ibrutinib retreatment in Phase 2 CAPTIVATE study:
ash.confex.com/ash/2023/webpr...
Hodgkin Lymphoma
1. S1826 outcomes in older adults:
ash.confex.com/ash/2023/webpr...
Diffuse Large B-cell Lymphoma
1. Smart STOP study: Lenalidomide, Tafasitamab, Rituximab, and Acalabrutinib Alone and with Combination Chemotherapy for the Treatment of Newly Diagnosed Diffuse Large B-Cell Lymphoma
ash.confex.com/ash/2023/webpr...
2. Mosunetuzumab and Polatuzumab Vedotin Demonstrates Preliminary Efficacy in Elderly Unfit/Frail Patients with Previously Untreated Diffuse Large B-Cell Lymphoma
ash.confex.com/ash/2023/webpr...